Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
Ariel Israel, Eugene Merzon, Alejandro A. Schäffer, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 16, pp. 1532-1546
Open Access | Times Cited: 2106
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Rishi R. Goel, Mark M. Painter, Sokratis A. Apostolidis, et al.
Science (2021) Vol. 374, Iss. 6572
Open Access | Times Cited: 797
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 556
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2127-2135
Open Access | Times Cited: 534
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2136-2143
Open Access | Times Cited: 417
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 188
Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK
Nick Andrews, Elise Tessier, Julia Stowe, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 168
Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 141
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Regional Health - Americas (2022) Vol. 9, pp. 100198-100198
Open Access | Times Cited: 104
Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 70
Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
Ariel Israel, Yotam Shenhar, Ilan Green, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 95
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 71
Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 62
mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern
Rishi R. Goel, Mark M. Painter, Sokratis A. Apostolidis, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 61
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Robert W Aldridge, Alexei Yavlinsky, Vincent Nguyen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 55
Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
Alice S. Huang, Caroline Cicin‐Sain, Chloé Pasin, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 4, pp. 214.e1-214.e11
Open Access | Times Cited: 51
Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
Isaac Yeboah Addo, Frederick Dadzie, Sylvester Reuben Okeke, et al.
Archives of Public Health (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 46
Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium
Veerle Stouten, Pierre Hubin, Freek Haarhuis, et al.
Viruses (2022) Vol. 14, Iss. 4, pp. 802-802
Open Access | Times Cited: 45
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
Jérôme Barrière, Michel Carlès, Clarisse Audigier-Valette, et al.
European Journal of Cancer (2021) Vol. 162, pp. 182-193
Open Access | Times Cited: 51
Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression
Daniel R. Feikin, Melissa M. Higdon, Laith J. Abu‐Raddad, et al.
SSRN Electronic Journal (2021)
Open Access | Times Cited: 50
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 49
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records
Michiel J.M. Niesen, Colin Pawlowski, John C. O’Horo, et al.
JAMA Network Open (2022) Vol. 5, Iss. 4, pp. e227038-e227038
Open Access | Times Cited: 29
Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience
Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum, et al.
The Journal of Infectious Diseases (2021) Vol. 225, Iss. 5, pp. 785-792
Open Access | Times Cited: 40
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases
Michael D. Kappelman, Kimberly N. Weaver, Xian Zhang, et al.
The American Journal of Gastroenterology (2021) Vol. 117, Iss. 3, pp. 462-469
Closed Access | Times Cited: 40
Page 1 - Next Page

Scroll to top